Another cancer vaccine approach - Imlygic (T-VEC) – is based on the oncolytic virus that lyses tumor cells in vivo to release tumor-associated antigens and induce tumor-specific immunity with the aid of DC and monocyte activating GM-CSF expressed from a co-delivered gene encoding this cytokine71. The gene discussed is CSF2; the disease is neoplasm.